Correction: The rationale for using rifabutin in the treatment of mdr and xdr tuberculosis outbreaks (PLoS ONE (2015) 8:3 (E59414) Doi:10.1371/journal.pone.0059414);The Rationale for Using Rifabutin in the Treatment of MDR and XDR Tuberculosis Outbreaks

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Sirgel, Frederick A ^a   Warren, Robin M ^a   Böttger, Erik C ^b   Klopper, Marisa ^a   Victor, Thomas C ^a   van Helden, Paul D ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

RIFABUTIN; RIFAMPICIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATION; CODON; CONCENTRATION RESPONSE; CROSS RESISTANCE; EPIDEMIC; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GENE MUTATION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; RPOB GENE; SINGLE NUCLEOTIDE POLYMORPHISM;

MYCOBACTERIUM TUBERCULOSIS;

EID: 84875394799     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0134190     Document Type: Erratum

References (24)

1. Telenti A, Imboden P, Marchesi F, Lowrie D, Cole S, et al. (1993) Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 341: 647-650.
2. Zaczek A, Brzostek A, Augustynowicz-Kopec E, Zwolska Z, Dziadek J, (2009) Genetic evaluation of relationship between mutations in rpoB and resistance of Mycobacterium tuberculosis to rifampin. BMC Microbiol 9: 10 doi:10.1186/1471-2180-9-10. Available: http://www.biomedcentral.com/1471-2180/9/10. Accessed 17 December 2012.
3. Anthony RM, Schuitema ARJ, Bergval IL, Brown TJ, Oskam L, et al. (2005) Acquisition of rifabutin resistance by a rifampicin resistant mutant of Mycobacterium tuberculosis involves an unusual spectrum of mutations and elevated frequency. Ann of Clin Microbiol Antimicrob 4: 9. Available: http:/www.ann-clinmicrob.content/4/1/9. Accessed 17 December 2012.
4. Bahrmand AR, Titov LP, Tasbiti AH, Yari S, Graviss EA, (2009) High-level rifampin resistance correlates with multiple mutations in the rpoß gene of pulmonory tuberculosis isolates from the Afghanistan border of Iran. J Clin Microbiol 47: 2744-2750.
5. Tan Y, Hu Z, Zhao Y, Cai X, Luo C, et al. (2012) The beginning of the rpoß gene in addition to the Rifampin Resistance Determination Region might be needed for identifying rifampin/rifabutin cross-resistance in multidrug-resistant Mycobacterium tuberculosis isolates from Southern China. J Clin Microbiol 50: 81-85.
6. Patra SK, Jain A, Sherwal BL, Khanna A, (2010) Rapid detection of mutation in RRDR of rpo B gene for rifampicin resistance in MDR-pulmonary tuberculosis by DNA sequencing. Ind J Biochem 25: 315-318.
7. Williams DL, Spring L, Collins L, Miller LP, Heifets LB, et al. (1998) Contribution of rpoß mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrobial Agents Chemother 42: 1853-1857.
8. Cavusoglu C, Karaca-Derici Y, Bilgic A, (2004) In-vitro activity of rifabutin against rifampicin-resistant Mycobacterium tuberculosis isolates with known rpoß mutations. Clin Microbiol Infect 10: 662-665.
9. Van Ingen J, Aarnoutse R, de Vries G, Boeree MU, van Soolingen D, (2011) Low level rifampicin-resistant Mycobacterium tuberculosis strains raise a new therapeutic challenge. Int J Tuberc Lung Dis 15: 990-992.
10. Yoshida S, Suzuki K, Iwamoto T, Tsuyuguchi K, Tomita M, et al. (2010) Comparison of rifabutin susceptibility and rpoB mutations in multi-drug-resistant Mycobacterium tuberculosis strains by DNA sequencing and the line probe assay. J Infect Chemother 16: 360-363.
11. Klopper M, Warren RM, Hayes C, Gey van Pittius NC, Streicher EM, et al. (2013) Comparative genomics of MDR-TB isolates from the Eastern Cape, South Africa suggests the emergence of totally drug resistant TB. Emerging Infec Dis 19 (3): In press.
12. Perlman D, Segal Y, Rosenkranz S, Rainey PM, Remmel RP, et al. (2005) The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis. Clin Infect Dis 41: 1638-1647.
13. Springer B, Lucke K, Calligaris-Maibach R, Ritter C, Böttger EC (2009) Quantitative drug susceptibility testing of Mycobacterium tuberculosis by use of MGIT 960 and EpiCenter instrumentation. J Clin Microbiol 47: 1773-1780. Available: http://www.ncbi.nlm.nih.gov/pubmed/19339475. Accessed 17 December 2012.
14. World Health Organization (WHO), Geneva, Switzerland. Policy guidance on drug-susceptibility testing (DST) of second line antituberculosis drugs. WHO/HTM/TB/2008.392: WHO, 2008: 1-20. Available: http://www.who.int/tb/publications/2008/whohtmtb_2008_392/en/index.html. Accessed 17 December 2012.
15. Ängeby K, Juréen P, Kahlmeter G, Hoffner SE, (2012) Schön (2012) Challenging a dogma: antimicrobial susceptibility testing breakpoints for Mycobacterium tuberculosis. Bull World Health Organ 90: 693-698 doi:10.2471/BLT.11.096644.
16. Chen H-Y, Yu M-C, Huang W-L, Wu M-H, Chang Y-L, et al. (2012) Molecular detection of rifabutin-susceptible Mycobacterium tuberculosis. J Clin Microbiol 50: 2085-2088.
17. Van Ingen J, de Lange WCM, Boeree MJ, Iseman MD, Daley CL, et al. (2011) XDR tuberculosis. Lancet Infect Dis 11: 585.
18. Van Deun A, Barrera L, Bastian I, Fattorini L, Hoffman H, et al. (2009) Mycobacterium tuberculosis strains with highly discordant rifampin susceptibility test results. J Clin Microbiol 47: 3501-3506.
19. Jo K-W, Ji W, Hong Y, Lee S-D, Kim WS,et al. (2013) The efficacy of rifabutin for rifabutin-susceptible, multidrug-resistant tuberculosis. Respir Med 107: 292-297.
20. Kunin CM (1996) Antimicrobial activity of rifabutin. Clin Infect Dis (Suppl 1): S3-14.
21. Böttger EC, (2011) The ins and outs of Mycobacterium tuberculosis drug susceptibility testing. Clin Microbiol Infect 17: 1128-1134.
22. Sirgel FA, Warren RM, Streicher EM, Victor TC, van Helden PD, et al. (2012) embB306 Mutations as molecular indicators to predict ethambutol susceptibility in Mycobacterium tuberculosis. Chemother 58: 358-363 doi:10.1159/000343474.
23. Sirgel FA, Warren RM, Streicher EM, Victor TC, van Helden PD, et al. (2012) gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis. J Antimicrob Chemother 67: 1088-1093.
24. Sirgel FA, Tait M, Warren RM, Streicher EM, Böttger EC, et al. (2012) Mutations in the rrs A1401G gene and phenotypic resistance to amikacin and capreomycin in Mycobacterium tuberculosis. Microbl Drug Resist 18: 193-197.